Abstract:Sida Chen, Ling Wen, Jintao Ou, Yuting Lai, Yan Shen Department of Respiratory, Shenzhen Longgang Central Hospital, Shenzhen, Guangdong, 518000, People's Republic of China Correspondence: Yan Shen, Shenzhen Longgang Central Hospital 6082 Longgang Boulevard (Longgang Section), Longgang District, Shenzhen, Guangdong, 518000, People's Republic of China, Tel +86-0755-84806933-5901, Email Background: Pulmonary infections are significant global health burdens, and conventional diagnostic methods (culture and polymerase chain reaction), are often limited by slow results and low sensitivity. Metagenomic next-generation sequencing (mNGS) offers a rapid, comprehensive alternative for identifying diverse pathogens, including rare and mixed infections. Thus, we assessed the diagnostic performance of mNGS in pulmonary infections, compared the findings with those of traditional pathogen detection methods, and explored its potential to enhance clinical diagnostics and patient care. Methods: We collected samples from 125 immunocompromised patients diagnosed with pulmonary infection at the Department of Respiratory Medicine of Shenzhen Longgang Central Hospital from March 2020 to July 2022. We compared the rate of pathogen positivity and pathogen distribution between conventional pathogen detection methods and mNGS using samples including sputum, blood, and bronchoalveolar lavage fluid. Results: Among the 125 cases of unexplained pulmonary infection, 82 (65.6%) and 40 (32.0%) tested positive for pathogens using mNGS and routine culture, respectively (P < 0.05). Both methods of pathogen detection were positive in 28 (22.4%) cases (complete match, 9; complete mismatch, 13; partial match, 6). However, 43.2% of cases only tested positive using mNGS, 9.4% only tested positive using routine tests, and 24.8% tested negative using both methods. A viral infection was present in 55.2% of cases. The detection rate of mycobacteria using mNGS (12.8%) was higher than that using conventional pathogen detection methods (5.6%). Conclusion: mNGS technology enhances pathogen detection in unexplained pulmonary infections, enabling targeted antimicrobial therapy and consequently helping to reduce broad-spectrum antibiotic use, aligning treatments more closely with the causative pathogens. Thus, mNGS offers significant clinical value by improving treatment efficacy and potentially reducing antibiotic resistance in pulmonary infection cases. Keywords: mNGS, Unexplained pulmonary infection, Pathogens, BALF Pulmonary infection is the most common type of infectious disease. It is caused by a single or mixed infection of microorganisms, including bacteria, fungi, and viruses. Over the past few decades, the gradual increase in the aging Chinese population has led to increased year-on-year mortality due to pulmonary infection. 1 The etiology of most pulmonary infections is unclear. 2 Additionally, the current abuse of antibiotics in China is a critical issue, placing a great burden on healthcare resources. 3 It is difficult to use targeted drugs to treat an infection when the causative pathogen is uncertain. This aggravates the patient's condition and may even lead to death. Therefore, accurate and timely diagnosis of the cause of infection and the reduction of unnecessary antibiotic use are crucial for treating pulmonary infection. 4 Although conventional microbiological tests (CMTs), including microbial culture, immunology, 5 and polymerase chain reaction (PCR), 6,7 can identify the pathogens of some pulmonary infectious diseases, they are time-consuming and have a low detection rate. Furthermore, the use of antibiotics prior to sample collection reduces the rate of pathogen-positive cultures. More importantly, viruses, parasites, Mycoplasma, Chlamydia , and other atypical pathogens are difficult to culture and are vulnerable to the interference of bacteria that colonize the respiratory tract. 8 Immunological testing and PCR cannot detect unknown pathogens. 6,7 Thus, the diversity of pathogens, the emergence of multidrug-resistant pathogens, and the occurrence of mixed infections mean that conventional etiological tests are unable to meet clinical needs. 9,10 Metagenomic next-generation sequencing (mNGS) has the advantages of high throughput, unbiased detection, and a short detection time. 11 Kawabata et al 12 found that mNGS detected pathogens quickly and provided clear guidance on antibiotic treatment. mNGS is capable of detecting thousands of pathogens simultaneously, which may greatly improve diagnostic efficiency. Furthermore, mNGS results are not influenced by antibiotic use. 11,13,14 Therefore, mNGS is a potential comprehensive -Abstract Truncated-

Enhanced DNA and RNA pathogen detection via metagenomic sequencing in patients with pneumonia

The Application of Nanopore Targeted Sequencing for Pathogen Diagnosis in Bronchoalveolar Lavage Fluid of Patients with Pneumonia: a Prospective Multicenter Study.

Clinical Impact of Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage in the Diagnosis and Management of Pneumonia A Multicenter Prospective Observational Study

Improving pulmonary infection diagnosis with metagenomic next-generation sequencing of bronchoalveolar lavage fluid

Microbiological diagnostic performance of metagenomic next-generation sequencing compared with conventional culture for patients with community-acquired pneumonia

Advantages in pathogen detection of bronchoalveolar lavage fluid by metagenomic next-generation sequencing in severe pneumonia

A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification

Diagnostic value of DNA or RNA-based metagenomic next-generation sequencing in lower respiratory tract infections

Utilizing metagenomic next-generation sequencing for pathogen detection and diagnosis in lower respiratory tract infections in real-world clinical practice

Diagnostic performance of metagenomic sequencing in patients with suspected infection: a large-scale retrospective study

Clinical application of metagenomic next‐generation sequencing technology in the diagnosis and treatment of pulmonary infection pathogens: A prospective single‐center study of 138 patients

Enhancing lower respiratory tract infection diagnosis: implementation and clinical assessment of multiplex PCR-based and hybrid capture-based targeted next-generation sequencing

Etiology of lower respiratory tract in pneumonia based on metagenomic next-generation sequencing: a retrospective study

Nanopore Sequencing Technology: A Reliable Method for Pathogen Diagnosis in Elderly Patients with Community-Acquired Pneumonia

Clinical values of metagenomic next-generation sequencing in patients with severe pneumonia: a systematic review and meta-analysis

A Retrospective Paired Comparison Between Untargeted Next Generation Sequencing and Conventional Microbiology Tests With Wisely Chosen Metagenomic Sequencing Positive Criteria

Application of metagenomic next-generation sequencing technology in the pathogenic detection of community-acquired pneumonia

Application of metagenomic next-generation sequencing (mNGS) in diagnosing pneumonia of adults

Metagenomic next-generation sequencing for the detection of pathogenic microorganisms in patients with pulmonary infection.

Exploring the Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Unexplained Pulmonary Infection

Application of the second-generation sequencing technology of metagenomics in the detection of pathogens in respiratory patients